DE3778651D1 - Steroide 17-alpha-silylaether-derivate und herstellung von corticoiden und progesteronen. - Google Patents

Steroide 17-alpha-silylaether-derivate und herstellung von corticoiden und progesteronen.

Info

Publication number
DE3778651D1
DE3778651D1 DE8787309664T DE3778651T DE3778651D1 DE 3778651 D1 DE3778651 D1 DE 3778651D1 DE 8787309664 T DE8787309664 T DE 8787309664T DE 3778651 T DE3778651 T DE 3778651T DE 3778651 D1 DE3778651 D1 DE 3778651D1
Authority
DE
Germany
Prior art keywords
corticoids
alpha
progesterones
production
steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787309664T
Other languages
English (en)
Inventor
Douglas Alan Livingston
Bruce Allen Pearlman
Scott Denmark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of DE3778651D1 publication Critical patent/DE3778651D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE8787309664T 1986-11-05 1987-11-02 Steroide 17-alpha-silylaether-derivate und herstellung von corticoiden und progesteronen. Expired - Fee Related DE3778651D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92763386A 1986-11-05 1986-11-05
US2045787A 1987-03-02 1987-03-02

Publications (1)

Publication Number Publication Date
DE3778651D1 true DE3778651D1 (de) 1992-06-04

Family

ID=26693463

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787309664T Expired - Fee Related DE3778651D1 (de) 1986-11-05 1987-11-02 Steroide 17-alpha-silylaether-derivate und herstellung von corticoiden und progesteronen.

Country Status (15)

Country Link
US (1) US4977255A (de)
EP (2) EP0268400B1 (de)
JP (2) JP2549721B2 (de)
KR (1) KR960006394B1 (de)
AT (1) ATE75484T1 (de)
AU (1) AU8335587A (de)
CA (1) CA1317283C (de)
DE (1) DE3778651D1 (de)
ES (1) ES2039249T3 (de)
GR (1) GR3005079T3 (de)
HK (1) HK69595A (de)
HU (2) HU892262D0 (de)
PT (1) PT86083B (de)
SG (1) SG33647G (de)
WO (1) WO1988003534A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081205C (en) * 1990-06-11 2001-02-27 John W. Wilks Steroids which inhibit angiogenesis
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
AU684946B2 (en) * 1994-05-09 1998-01-08 Pharmacia & Upjohn Company SYNTHESIS OF 17B CYANO-3-ETHOXY-17a-HYDROXY-6-METHYLANDROSTA-3,5,9-(11)-TRIEN 9(11)-triene
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
AU4584901A (en) 2000-03-17 2001-10-15 Us Gov Health & Human Serv Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
KR100694079B1 (ko) 2005-01-08 2007-03-12 학교법인 대양학원 유무선 통합 네트워크에서 ｐ２ｐ 서비스를 위한 데이터다운로드 방법 및 그 노드
KR101591482B1 (ko) * 2008-05-28 2016-02-03 레베라겐 바이오파마 인코포레이티드 질환의 치료를 위한 ＮＦ-κＢ 의 비호르몬성 스테로이드 조절제
EP2556083A4 (de) 2010-04-05 2013-12-04 Validus Biopharma Inc Nichthormonale steroide modulatoren von nf-kappa-b zur krankheitsbehandlung
CN103601786A (zh) * 2013-11-22 2014-02-26 湖南新合新生物医药有限公司 甲基泼尼松龙关键中间体的制备方法
CN103833814A (zh) * 2014-03-06 2014-06-04 浙江仙居君业药业有限公司 17羟基-孕甾-4-烯-3,20-二酮-21-醋酸酯的制备方法
CN103910775A (zh) * 2014-03-31 2014-07-09 仙居县圃瑞药业有限公司 17α-羟基黄体酮的合成方法
CN104311619A (zh) * 2014-07-08 2015-01-28 仙居县圃瑞药业有限公司 一种采用串联法合成黄体酮的方法
CN104311625B (zh) * 2014-11-06 2016-03-23 江西赣亮医药原料有限公司 一种醋酸氟轻松中间体的制备方法
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN105801651B (zh) * 2016-04-19 2018-03-06 浙江仙居君业药业有限公司 一种17α‑羟基黄体酮的合成方法
CN109517020B (zh) * 2018-11-22 2020-12-15 湖南原野医药有限公司 Delta-9,11-羟基黄体酮的合成方法
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
CN117257775A (zh) * 2023-11-01 2023-12-22 南京羚诺生物医药技术研究院有限公司 一种子宫内膜异位症用口溶膜制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2082129A5 (de) * 1970-03-04 1971-12-10 Roussel Uclaf
SE387854B (sv) * 1973-11-21 1976-09-20 O L Lindblad Paverkningsorgan, foretredesvis avsett att anvendas i samband med fordonsekerhetsselar
US4081537A (en) * 1975-10-10 1978-03-28 Schering Aktiengesellschaft Δ15 -Steroids and pharmaceutical compositions thereof
JPS5762298A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-cyanosteroid
JPS5762299A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-cyanosteroid
JPS5762296A (en) * 1980-10-01 1982-04-15 Mitsubishi Chem Ind Ltd Preparation of 17alpha-hydroxyprogesterone derivative
EP0153001B1 (de) * 1984-02-03 1992-03-11 The Upjohn Company Steroide mit einer Enamid- oder Enimidgruppe sowie ihre Herstellung
US4500461A (en) * 1984-02-03 1985-02-19 The Upjohn Company Cyanohydrin process
US4548748A (en) * 1984-02-03 1985-10-22 The Upjohn Company Cyanohydrin process
US4585590A (en) * 1984-02-03 1986-04-29 The Upjohn Company Cyanohydrin process
DE3427486A1 (de) * 1984-07-23 1986-01-30 Schering AG, Berlin und Bergkamen, 1000 Berlin Verfahren zur herstellung von 6(alpha)-methylsteroiden

Also Published As

Publication number Publication date
SG33647G (en) 1995-09-01
EP0268400A1 (de) 1988-05-25
ATE75484T1 (de) 1992-05-15
EP0268400B1 (de) 1992-04-29
EP0334875A1 (de) 1989-10-04
HK69595A (en) 1995-05-12
JP2515967B2 (ja) 1996-07-10
GR3005079T3 (de) 1993-05-24
US4977255A (en) 1990-12-11
HU892262D0 (en) 1992-09-28
HUT65138A (en) 1994-04-28
PT86083A (en) 1987-12-01
JPH02500911A (ja) 1990-03-29
KR890700130A (ko) 1989-03-10
JPH07278183A (ja) 1995-10-24
HU209783B (en) 1994-10-28
JP2549721B2 (ja) 1996-10-30
ES2039249T3 (es) 1993-09-16
KR960006394B1 (ko) 1996-05-15
WO1988003534A1 (en) 1988-05-19
PT86083B (pt) 1990-11-20
AU8335587A (en) 1988-06-01
CA1317283C (en) 1993-05-04

Similar Documents

Publication Publication Date Title
DE3778651D1 (de) Steroide 17-alpha-silylaether-derivate und herstellung von corticoiden und progesteronen.
GB2014387B (en) Differential to single-ended converter utilizing inverted transistors
DE69026503D1 (de) Verfahren zur Herstellung von Bauelementen mit übereinander angeordneten selbstjustierten Feldeffekttransistoren aus Polisilizium und sich daraus ergebende Struktur
AU8062487A (en) New substituted cephalosporin sulfones as anti-inflammatory and antidegenerative agents
FI860483A0 (fi) Komposition och foerfarande foer flotation av stenkol ur raostenkol.
HUT45399A (en) Production of seditive compositions by applying medetomidine
GB2136652B (en) Differential amplifier with bipolar transistors
FI873125A (fi) Foerfarande foer framstaellning av 5,6-substituerade 2,4-kinazolindiaminer samt nya mellanprodukter.
ATE51229T1 (de) Oxa- und thiadiazolylderivate und ihre verwendung.
ES451701A1 (es) Procedimiento para la obtencion de y-lactonas de acidos 6 beta, 17-dihidroxi-7 alfa-(alcoxi inferior) -carbonil-3-oxo-17 alfa'pregn-4-eno-21-carboxilicos.
IT7829388A0 (it) Amplificatore lineare differenziale con entrate collegabili ad uno dei poli di alimentazione ed uscita single-ended.
AU533275B2 (en) 2-amino or 2-thio derivatives of 4,5-diphenyl-oxazole
ES8106156A1 (es) Un procedimiento para la preparacion de derivados de oxadia-zolotriazona
ATE71671T1 (de) Methylenchloridzusammensetzung und deren verwendung zum entfetten von metallen.
AU499324B2 (en) D-homo pregna 1, 4 diene-3, 11, 20 trione derivatives
DE3672635D1 (de) Esterderivate von 2,2-dimethyl-3-ethenylcyclopropancarbonsaeure, ihre herstellung, ihre verwendung als parasitizide und sie enthaltende zusammensetzungen.
KR790000569B1 (en) Method of producting 62-fluoro-17,21-dehydroxy-16b-methylpregna-4,9(11)-diene-3,20-dione 17,21-diacetate
ATE81129T1 (de) Carbapenem-verbindung in kristalliner form und ihre herstellung und verwendung.
GR900100749A (el) Μέ?οδος λήψεως νέων αλκοϋλο παραγώγων εις τα 17/21 της 19-NOR προγεστερόνης.
ATE6007T1 (de) Verfahren zur herstellung von solarzellenpaneelen und durch dieses verfahren erhaltene paneele.
ATE6783T1 (de) Zwischenprodukte in der herstellung von 2substituierten 19-nor-steroiden.
ES2053474T3 (es) 1,2,3-tiadazol-4-tiolatos substituidos.
JPS5353947A (en) Amplifier

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN CO., KALAMAZOO, MICH., US

8339 Ceased/non-payment of the annual fee